French biotech moves on with the late stage drug development, after publishing impressive clinical trial results of ABX464 for treatment of colitis and hinting its potential in Crohn’s disease ...

Eli Lilly has said it plans to file its anti-IL-23p19 antibody mirikizumab for approval as a treatment for Crohn’s disease next year after it hit all its targets in a phase 3 trial.

The diagnostic process for patients who have noninfectious and non-IBD forms of colitis is often burdensome because of our limited knowledge of these conditions. This Review discusses the ...